Ultrapurification of Biomacromolecules

最近在基因工程方面取得的显著进展使用于人类健康保健的治疗性蛋白质的工业规模生产成为可能。随着新的生产方法的引入，出现了巨大的净化挑战。为了避免污染物的副作用（其中许多是未知的），治疗蛋白必须被超纯化到超出当前技术范围的水平。因此，迫切需要可应用于工业规模的新型分离和净化技术。这项由多名研究者参与的研究旨在整合几种创新技术ısuch，如高效液相色谱（HPLC）、电泳和超临界流体分离！为生物大分子的工业超纯化提供依据。这种新的纯化和分离技术的应用将在重组组织型纤溶酶原激活剂上进行测试，这是一种用于治疗心脏病患者的救命药物。

The remarkable recent advances in genetic engineering now allow industrial-scale production of therapeutic proteins for human health care. With the introduction of new production methods have come immense purification challenges. In order to avoid untoward side effects of contaminants (many of which are as yet unknown), therapeutic proteins must be ultra-purified to levels beyond the scope of present technology. Thus, there is a great need for novel separation and purification techniques which may be applied on an industrial scale. This multi-investigator study is an effort to integrate several innovative technologies ısuch as High Performance Liquid Chromatography, (HPLC), electrophoresis, and supercritical-fluid based separations! to provide a basis for industrial ultrapurification of biomacromolecules. Applications of such new purification and separation technologies will be tested on recombinant tissue plasminogen activator, a life-saving therapeutic used in the treatment of heart attack victims.